Back to news overview

Novo Nordisk makes an offer on Ablynx

Danish pharma multinational Novo Nordisk announced that it is willing to pay €2.6 billion for Ablynx, but the VUB biotech spin-off finds it too little. The Ablynx board concluded that the proposal undervalues the company and its strong prospects for growth, its technology and know how.

Read the press release here and the article in De Tijd.